On the occasion of the 43rd J.P. Morgan Healthcare Conference in San Francisco, Bayer AG announces further progress in its pharmaceutical growth strategy with multiple regulatory filing submissions ...

The addition of Truqap to standard-of-care therapy improved radiographic progression-free survival in patients with ...

A MAN suffering from a common cancer was forced to have his entire penis amputated after it spread to his manhood, in what ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

Research suggests a new drug slowed the growth of prostate cancer cells, including those with a resistance to the hormone ...

An auto-recruit program improved DXA screening and bone health management in men with prostate cancer receiving androgen-deprivation therapy.

Evan Y. Yu, MD, discusses how the ARANOTE study, which evaluated androgen deprivation therapy (ADT) plus darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC), aimed to assess the ...

New consensus recommendations address implementation of novel treatments and imaging techniques for advanced and ...

Researchers conducted a post hoc, retrospective, cross-sectional analysis of 182 patients with recurrent prostate cancer ...

Advanced Imaging Reveals Undetected Metastases in High-Risk Prostate Cancer Patients: Study FindsA new study published in JAMA Network Open, found ...

Orion's collaboration partner Bayer has submitted an application to the Center of Drug Evaluation (CDE) of China's National ...

Bayer seeks China NMPA marketing authorization for ARi darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, January 8, 2 ...